Soleno Therapeutics is developing therapeutics for rare diseases, including Prader-Willi Syndrome, and Anish Bhatnagar serves as CEO and Chairman of the Board.
2 reports, 0 independent
Updated Jun 25
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Soleno Therapeutics is developing therapeutics for rare diseases, including Prader-Willi Syndrome, and Anish Bhatnagar serves as CEO and Chairman of the Board.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Soleno Therapeutics focuses on rare disease therapeutics like PWS, with Anish Bhatnagar leading the company.
- Soleno plans to file treatments for Prader-Willi syndrome with the European Medicines Agency.
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet